Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC. Sanford DE, et al. Among authors: goedegebuure sp. J Cancer Ther. 2013 May;4(3):797-803. doi: 10.4236/jct.2013.43096. J Cancer Ther. 2013. PMID: 24089656 Free PMC article.
Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.
Wilkinson-Ryan I, Kim J, Kim S, Ak F, Dodson L, Colonna M, Powell M, Mutch D, Spitzer D, Hansen T, Goedegebuure SP, Curiel D, Hawkins W. Wilkinson-Ryan I, et al. Among authors: goedegebuure sp. PLoS One. 2015 May 1;10(5):e0125851. doi: 10.1371/journal.pone.0125851. eCollection 2015. PLoS One. 2015. PMID: 25933160 Free PMC article.
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC. Nywening TM, et al. Among authors: goedegebuure sp. Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4. Lancet Oncol. 2016. PMID: 27055731 Free PMC article. Clinical Trial.
Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG. Ohman KA, et al. Among authors: goedegebuure sp. Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551. Oncotarget. 2016. PMID: 27244881 Free PMC article.
Development of an adenovirus vector vaccine platform for targeting dendritic cells.
Sharma PK, Dmitriev IP, Kashentseva EA, Raes G, Li L, Kim SW, Lu ZH, Arbeit JM, Fleming TP, Kaliberov SA, Goedegebuure SP, Curiel DT, Gillanders WE. Sharma PK, et al. Among authors: goedegebuure sp. Cancer Gene Ther. 2018 Feb;25(1-2):27-38. doi: 10.1038/s41417-017-0002-1. Epub 2017 Dec 15. Cancer Gene Ther. 2018. PMID: 29242639 Free PMC article.
60 results